Member Info for Oxmil

“Get rid of the wfh nonsense” so you want to pay tens of k a month for a flashy office and salary for a tea girl? Not too sure how that solves cash flow or brings in new projects and does the R&D that actually creates value

So you knew what he was being paid once, was that recently? Who knows what’s changed since then.

Don’t they all have second jobs anyway?

If you’d watched the video that went with the RNS you’d know exactly who has left, or even just look on the website team page

The whole list of people who were 100% cut wasn’t enough for you then viera? The guy you don’t like got to stay so that’s it. How do you know his salary anyway? Isn’t that personal, private info until he’s made a director?

Any more cutting and there will be no one left to do the work. ME might be brilliant but it isn’t the best use of his time if he has to deal with every website update or hiccup, all the commercial and all the science. Without support staff there will be no time left for science and no point to having the company at all

Amazingly small discount, most biotech on here are taking 50% cuts to get a fundraise away at the moment

The VAL website is updated, doesn’t look like the Inaphaea one is yet though

Don’t you just hit the nail on the head with your first line though? Didn’t know what you were getting into. Biotech is always a long term play. Drugs take decades to be fully developed with just a few opportunities to pass them on at a premium to bigger companies during the process.

AIM is full of investors who don’t understand the companies they’ve invested in.

The scientists just assume that investors know what they’re doing and know the risks, but most are just in because they’ve read a tip on a website somewhere.

Does that make it fraud or buyer beware

Could 201 really ever have been worth anything though? Didn’t GM used to claim he pulled it out of a bin at Cancer Research UK? Perhaps it was there because they knew what it was really worth already

The biggest thing the FCA will ask is why the price moved as it did just before. It would be good to get reassurance that the sellers were just speculating that there was a problem rather than insiders selling

As non-exec chair, presumably he was brought in by KC to take over from him rather than SD. Even with this, his biotech experience still outweighs the rest of the non exec board.

How long has he been here for now? 18 months? The share price has been pretty stable over most of that period which it certainly hadn’t been before that and sales seem to be building up. Something odd has happened over the past few weeks, but given his performance up to that point I’d say either something drastic has happened behind the scenes, or it’s about to turnaround and get back to where it normally is

It’s not going to be a placing while they’re keeping the spread that low.

Reason for the drop? Just that there was no reason for the rise in the first place. Some stayed to see if there was a reason, turns out there isn’t so they’ve moved to the next quick buck

Nigel’s overheads always seem pretty lean compared to most aim biotechs, if he’s clear about what the funding will be used for and why it will increase shareholder value then I don’t think it’s unreasonable for him to ask. IIs might look more favourably with Alastair on board if they backed him at Avacta

If they’ve brought Alastair in to replace the chief scientist who retired, then it looks like they’re concentrating more on commercial than science. Alastair is a scientist but he’s a very commercial one

They sound very comfortable together, as he’s quite new that’s great to see. They must be working together a lot. Good to see a NED working hard

Anyone else online at the moment, just listening to Alastair’s intro, good to hear more about why he’s here

Is that viera calling for yet another new CEO already? I think that shows he’s already completely sold out again after the placing. No need to put a TR1 out if you don’t hold them long enough to write it. And no need to hold the placing shares if you keep the warrants. He’ll have got his 20% profit and now has the warrants as free carry. Easy profits if you can do it

Suggesting a new CEO is just trying to cause disquiet as there’s already months of lost research time last year so no one who holds will want to do that again without seeing where ME takes it first

Is Slater selling? I expect so, he does tend to pull people in with a well timed TR-1, but those people come in by buying his shares so he’s left pocketing the cash ready for the next one and the newbies are spiked. Did you fall for it again?

I think he’s only seen in a negative light by shareholders who got their timing wrong on investing. Most AIM biotech share prices came down at the end of Covid, just as most went up at the beginning. Anyone who thinks that the price went down because of one individual whether at Avacta or N4P isn’t looking at the market trends but just really narrowly at one company.

AS did a great job of making hay while the sun shone at Avacta, it will be interesting to see how he does elsewhere on a rainy day.

Regardless, he must have had plenty of job opportunities recently, with experience in building a company up and running it, so he must see something good here to have joined.

Then post those questions on the investor hub and see if you get an answer